Merck Stock Drops 2.28% on $8.38 Billion Trading Day Ranking 100th in Volume

On May 1, 2025, Merck (MRK) experienced a significant decline, with its stock price dropping by 2.28%. The trading volume for the day was substantial, reaching $8.38 billion, which placed it at the 100th position in terms of trading volume for the day.

Merck has recently made a substantial investment in its future production capabilities. The company has broken ground on a new $1 billion biologics center of excellence in Wilmington, Delaware. This 470,000-square-foot facility will serve as a hub for laboratory, manufacturing, and warehouse operations, positioning it as a key production site for Keytruda, one of Merck's flagship products.

In addition to this significant investment, Merck has also reported strong financial performance. The company's Q4 and full-year 2024 results showed robust growth, with worldwide sales reaching $15.6 billion for the fourth quarter and $64.2 billion for the full year, representing a 7% increase from the previous year. This growth reflects the strong demand for Merck's innovative portfolio, including Keytruda and other key products.

Merck's commitment to innovation and its science-led strategy continue to drive long-term value for patients, employees, and shareholders. The company's diverse pipeline, which includes over 80 Phase II programs, 30 Phase III programs, and 10 programs under review, underscores its relentless pursuit of the next breakthrough in healthcare.